论文部分内容阅读
目的探讨重组人血管内皮抑素静脉泵入联合化疗在晚期结肠癌治疗中的疗效及安全性。方法 36例晚期结肠癌患者采用重组人血管内皮抑素持续静脉泵入联合化疗。重组人血管内皮抑素注射液15mg/(m2·d),连续14d;在第4d开始化疗,化疗方案选用XELOX、m FOLFOX6、FOLFIRI。结果 36例患者均完成至少2个周期的治疗,完全缓解1例,部分缓解15例,稳定14例,进展6例,有效率(RR)为44.4%。治疗过程中与重组人血管内皮抑素相关的主要不良反应为1例2级窦性心动过速;化疗不良反应主要为主要表现为中性粒细胞减少、恶心、呕吐、腹泻等,程度较轻,无化疗相关死亡。结论重组人血管内皮抑素静脉泵入联合化疗治疗晚期结肠癌的近期疗效较好,不良反应可耐受。
Objective To investigate the efficacy and safety of intravenous infusion of recombinant human endostatin combined with chemotherapy in the treatment of advanced colon cancer. Methods Thirty-six patients with advanced colon cancer were treated with recombinant human endostatin and continuous intravenous infusion of combined chemotherapy. Recombinant human endostatin injection 15mg / (m2 · d), continuous 14d; in the first 4d chemotherapy, chemotherapy options XELOX, m FOLFOX6, FOLFIRI. Results All the 36 patients completed at least 2 cycles of treatment. Complete remission was achieved in 1 case, partial remission in 15 cases, stabilization in 14 cases and progression in 6 cases. The effective rate (RR) was 44.4%. The main adverse reactions associated with recombinant human endostatin in the course of treatment were 1 case of grade 2 sinus tachycardia. The main adverse reactions of chemotherapy were mainly neutropenia, nausea, vomiting and diarrhea, with mild degree , No chemotherapy-related deaths. Conclusions Recombinant human endostatin intravenous pump combined with chemotherapy for advanced colon cancer has better curative effect in the near future and adverse reactions can be tolerated.